308 related articles for article (PubMed ID: 28611201)
1. Relationship of the Breast Ductal Carcinoma
Hendry S; Pang JB; Byrne DJ; Lakhani SR; Cummings MC; Campbell IG; Mann GB; Gorringe KL; Fox SB
Clin Cancer Res; 2017 Sep; 23(17):5210-5217. PubMed ID: 28611201
[No Abstract] [Full Text] [Related]
2. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
[TBL] [Abstract][Full Text] [Related]
4. Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.
Pang JB; Savas P; Fellowes AP; Mir Arnau G; Kader T; Vedururu R; Hewitt C; Takano EA; Byrne DJ; Choong DY; Millar EK; Lee CS; O'Toole SA; Lakhani SR; Cummings MC; Mann GB; Campbell IG; Dobrovic A; Loi S; Gorringe KL; Fox SB
Mod Pathol; 2017 Jul; 30(7):952-963. PubMed ID: 28338653
[TBL] [Abstract][Full Text] [Related]
5. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
Kim M; Choi HY; Woo JW; Chung YR; Park SY
Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
[TBL] [Abstract][Full Text] [Related]
6. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Kassardjian A; Shintaku PI; Moatamed NA
PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
[TBL] [Abstract][Full Text] [Related]
7. The PD-1/PD-L1 Axis in HER2+ Ductal Carcinoma In Situ (DCIS) of the Breast.
Ubago JM; Blanco LZ; Shen T; Siziopikou KP
Am J Clin Pathol; 2019 Jul; 152(2):169-176. PubMed ID: 30984969
[TBL] [Abstract][Full Text] [Related]
8. Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression.
Chatzopoulos K; Collins AR; Sotiriou S; Keeney MG; Visscher DW; Rivera M; Schembri-Wismayer DJ; Lewis JE; Greipp PT; Sukov WR; Chintakuntlawar AV; Price KA; Garcia JJ
Head Neck Pathol; 2020 Dec; 14(4):951-965. PubMed ID: 32350809
[TBL] [Abstract][Full Text] [Related]
9. Higher densities of tumour-infiltrating lymphocytes and CD4
Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
[TBL] [Abstract][Full Text] [Related]
10. Functional CD3
Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
[TBL] [Abstract][Full Text] [Related]
11. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
12. Immune Escape in Breast Cancer During
Gil Del Alcazar CR; Huh SJ; Ekram MB; Trinh A; Liu LL; Beca F; Zi X; Kwak M; Bergholtz H; Su Y; Ding L; Russnes HG; Richardson AL; Babski K; Min Hui Kim E; McDonnell CH; Wagner J; Rowberry R; Freeman GJ; Dillon D; Sorlie T; Coussens LM; Garber JE; Fan R; Bobolis K; Allred DC; Jeong J; Park SY; Michor F; Polyak K
Cancer Discov; 2017 Oct; 7(10):1098-1115. PubMed ID: 28652380
[TBL] [Abstract][Full Text] [Related]
13. Immune characterization of breast cancer metastases: prognostic implications.
Dieci MV; Tsvetkova V; Orvieto E; Piacentini F; Ficarra G; Griguolo G; Miglietta F; Giarratano T; Omarini C; Bonaguro S; Cappellesso R; Aliberti C; Vernaci G; Giorgi CA; Faggioni G; Tasca G; Conte P; Guarneri V
Breast Cancer Res; 2018 Jun; 20(1):62. PubMed ID: 29929548
[TBL] [Abstract][Full Text] [Related]
14. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
[TBL] [Abstract][Full Text] [Related]
15. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
[TBL] [Abstract][Full Text] [Related]
17. The immune microenvironment of breast ductal carcinoma in situ.
Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
19. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
[TBL] [Abstract][Full Text] [Related]
20. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous "healing" in HER2-positive ductal carcinoma in situ.
Morita M; Yamaguchi R; Tanaka M; Tse GM; Yamaguchi M; Kanomata N; Naito Y; Akiba J; Hattori S; Minami S; Eguchi S; Yano H
Cancer Med; 2016 Jul; 5(7):1607-18. PubMed ID: 27061242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]